BRPI0701664A2 - 4-quinolinonas e quinolinas, processo de preparaÇço, formulaÇÕes farmacÊuticas e uso das mesmas - Google Patents

4-quinolinonas e quinolinas, processo de preparaÇço, formulaÇÕes farmacÊuticas e uso das mesmas

Info

Publication number
BRPI0701664A2
BRPI0701664A2 BRPI0701664-6A BRPI0701664A BRPI0701664A2 BR PI0701664 A2 BRPI0701664 A2 BR PI0701664A2 BR PI0701664 A BRPI0701664 A BR PI0701664A BR PI0701664 A2 BRPI0701664 A2 BR PI0701664A2
Authority
BR
Brazil
Prior art keywords
quinolinones
pharmaceutical formulations
quinolines
preparation process
pharmaceutical
Prior art date
Application number
BRPI0701664-6A
Other languages
English (en)
Inventor
Correa Arlene Goncalves
Patricia Tambarussi Baraldi
Soares Andreimar Martins
Original Assignee
Fundacao Universidade Fed De Sco Carlos
Univ Sao Paulo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Universidade Fed De Sco Carlos, Univ Sao Paulo filed Critical Fundacao Universidade Fed De Sco Carlos
Priority to BRPI0701664-6A priority Critical patent/BRPI0701664A2/pt
Priority to PCT/BR2008/000151 priority patent/WO2008144865A2/en
Priority to US12/602,347 priority patent/US20100196476A1/en
Priority to EP08748073A priority patent/EP2167468A4/en
Priority to CA002689056A priority patent/CA2689056A1/en
Publication of BRPI0701664A2 publication Critical patent/BRPI0701664A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

4-QUINOLINONAS E QUINOLINAS, PROCESSO DE PREPARAÇçO, FORMULAÇÕES FARMACÊUTICAS E USO DAS MESMAS São descritas novas 4-quinolinonas correspondentes á fórmula (I) e derivados quinolina das mesmas de fórmula (II), o processo de preparação das mesmas, formulações farmacêuticas que contêm ditas 4-quinolinonas e a aplicação farmacêutica das mesmas em doenças relacionadas a desordens nas células brancas do sangue, tais como doenças autoimune e inflamatória, incluindo reumatismo, além do uso como anticoagulante, antiofídico, analgésico, e ação anti-trombose.
BRPI0701664-6A 2007-05-28 2007-05-28 4-quinolinonas e quinolinas, processo de preparaÇço, formulaÇÕes farmacÊuticas e uso das mesmas BRPI0701664A2 (pt)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BRPI0701664-6A BRPI0701664A2 (pt) 2007-05-28 2007-05-28 4-quinolinonas e quinolinas, processo de preparaÇço, formulaÇÕes farmacÊuticas e uso das mesmas
PCT/BR2008/000151 WO2008144865A2 (en) 2007-05-28 2008-05-23 Process for the preparation and pharmaceutical formulations for 4-quinolinones and quinolines and use thereof
US12/602,347 US20100196476A1 (en) 2007-05-28 2008-05-23 Process for the preparation and pharmaceutical formulations for 4-quinolinones and quinolines and use thereof
EP08748073A EP2167468A4 (en) 2007-05-28 2008-05-23 PROCESS FOR PREPARING AND PHARMACEUTICAL FORMULATIONS OF 4-CHINOLINONES AND CHINOLINES AND THEIR USE
CA002689056A CA2689056A1 (en) 2007-05-28 2008-05-23 Process for the preparation and pharmaceutical formulations for 4-quinolinones and quinolines and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0701664-6A BRPI0701664A2 (pt) 2007-05-28 2007-05-28 4-quinolinonas e quinolinas, processo de preparaÇço, formulaÇÕes farmacÊuticas e uso das mesmas

Publications (1)

Publication Number Publication Date
BRPI0701664A2 true BRPI0701664A2 (pt) 2009-01-13

Family

ID=40075565

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0701664-6A BRPI0701664A2 (pt) 2007-05-28 2007-05-28 4-quinolinonas e quinolinas, processo de preparaÇço, formulaÇÕes farmacÊuticas e uso das mesmas

Country Status (5)

Country Link
US (1) US20100196476A1 (pt)
EP (1) EP2167468A4 (pt)
BR (1) BRPI0701664A2 (pt)
CA (1) CA2689056A1 (pt)
WO (1) WO2008144865A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598354B2 (en) 2008-12-05 2013-12-03 University Of South Florida Compounds having antiparasitic or anti-infectious activity
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
WO2012048181A1 (en) 2010-10-08 2012-04-12 N30 Pharmaceuticals, Llc Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
BR112013014681A2 (pt) 2010-12-16 2016-10-04 N30 Pharmaceuticals Inc novos compostos aromáticos bicíclicos substituídos como inibidores de s-nitrosoglutationa redutase
JP6226318B2 (ja) 2013-09-02 2017-11-08 株式会社 資生堂 光学分割用化合物、光学分割用試薬、光学分割する方法及び光学異性体
US10399946B2 (en) 2015-09-10 2019-09-03 Laurel Therapeutics Ltd. Solid forms of an S-Nitrosoglutathione reductase inhibitor
US20220241521A1 (en) * 2021-02-02 2022-08-04 Freedom Corp. Device for fibrin-biopolymer-forming substance application
US20220241152A1 (en) * 2021-02-02 2022-08-04 Freedom Corp. Fibrin biopolymer formation and application device

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252945A (en) * 1979-07-11 1981-02-24 E. R. Squibb & Sons, Inc. Process for preparing pyrazolo[1,5-c]-quinazoline derivatives and novel intermediates
US4474788A (en) * 1981-11-12 1984-10-02 Fisons Plc Anti-SRSA quinoline carboxylic acid derivatives
CA2011086A1 (en) * 1989-03-17 1990-09-17 Karl-Heinz Geiss 2-alkyl-4-arylmethylaminoquinolines, the use thereof and drugs prepared therefrom
DE69016125T2 (de) * 1989-08-11 1995-06-01 Zeneca Ltd Chinolin-Derivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel.
JP2000212180A (ja) * 1999-01-21 2000-08-02 Welfide Corp キノリン化合物
PT1177176E (pt) * 1999-04-28 2006-08-31 Aventis Pharma Gmbh Derivados de acidos triarilicos como ligandos de receptores ppar.
JP2001261654A (ja) * 2000-03-21 2001-09-26 Mitsui Chemicals Inc キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬
CA2555050C (en) * 2004-02-18 2017-11-28 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthine derivatives, the production thereof and the use in the form of a dpp-iv inhibitor

Also Published As

Publication number Publication date
EP2167468A4 (en) 2011-03-23
EP2167468A2 (en) 2010-03-31
US20100196476A1 (en) 2010-08-05
CA2689056A1 (en) 2008-12-04
WO2008144865A2 (en) 2008-12-04
WO2008144865A3 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
BR112012032234A2 (pt) "derivados de heteroaril imidazolona como inibidores de jak".
BR122020008544B8 (pt) uso de 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas, e medicamento
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112015007231A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
BR112014026703A2 (pt) inibidores de dna-pk
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
NO20080408L (no) Azaindazolforbindelser og anvendelse derav
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
ECSP088975A (es) Nuevos análagos de piridina
EA200970835A1 (ru) Индазолы, применяемые для лечения расстройств, опосредуемых эстрогеновым рецептором бета
BR112014012479A2 (pt) derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas das agonistas de receptor 2 de canabinóide
ATE466002T1 (de) Substituierte benzo (d) isoaxol-3-yl-amin- verbindungen als analgetika
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
BR112015020795A2 (pt) derivados de pirazol novos
BRPI0412291A (pt) antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
UY30229A1 (es) Tetrahidro-pirimidoazepinas como moduladores de trpv1
BR112015006436A2 (pt) novas piridinonas bicíclicas
CO6361926A2 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales
BR112014010047A8 (pt) novos derivados de pirazina
CY1120375T1 (el) Υποκατεστημενο 1η-πυραζολο-5-ολικο νατριο
BR112015023356A2 (pt) inibidores de quinase pirrol[2,3-b]piridina cdk9

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]